Sensei Biotherapeutics (NASDAQ:FTH) Research Coverage Started at Citizens Jmp

Citizens Jmp started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report issued on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $51.00 target price on the stock.

Several other research firms have also recently issued reports on FTH. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Citigroup assumed coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target on the stock. Robert W. Baird started coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. Finally, Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $54.00.

Sensei Biotherapeutics Price Performance

NASDAQ FTH opened at $28.66 on Monday. The firm has a market capitalization of $38.40 million, a P/E ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson bought 9,391 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This trade represents a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. The trade was a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 49,494 shares of company stock valued at $1,188,822. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently modified their holdings of FTH. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares during the period. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.